The ability of small interfering RNA (siRNA) to inhibit mammalian gene expression is being exploited as a new class of therapeutics for a variety of diseases．However, the efficient and safe delivery of siRNAs into specific cell populations is still the principal challenge in the clinical development of RNAi therapeutics．Many potential delivery vehicles and vectors have been explored including the aptamers targeting cell surface proteins．Selected nucleic acid binding species (aptamers) are high affinity and specificity for their targets, and they have been effectively applied in targeted therapy and diagnostics of diseases．The aptamer-based delivery of siRNAs can often enhance the therapeutic efficacy and reduce the unwanted off-target effects of siRNAs．Nowadays, some kinds of aptamers are able to mediate the delivery of siRNA, such as anti-PSMA aptamer, anti-gp120 aptamer. I will review the latest progress about aptamer mediated siRNA．